|

A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis

RECRUITINGPhase 1Sponsored by Xencor, Inc.
Actively Recruiting
PhasePhase 1
SponsorXencor, Inc.
Started2025-10-21
Est. completion2028-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07230353

Summary

The purpose of this study is to determine the safety and tolerability of XmAb13676 in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: Adult participants with moderately to severely active RA.

* Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
* Inadequate response to, loss of response to, or intolerance to available RA therapies.
* Stable doses of RA medications prior to screening
* Use of highly effective methods of contraception

Exclusion Criteria:

* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
* Recurrent infections or active clinically significant infection
* Active or untreated latent tuberculosis
* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease

Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.

Conditions2

ArthritisRheumatoid Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.